Andrew Goetz - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Andrew Goetz

Showing results (11-20 of 21) with videos related to

Pageof 3

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002

Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesJohann S de Bono, Joseph Stephenson, Sharyn D Baker, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignanciesEric K Rowinsky, Jinee Rizzo, Leonel Ochoa, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005

Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomasJames A Posey, M Wasif Saif, Ronda Carlisle, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignanciesAmita Patnaik, Eric K Rowinsky, Miguel A Villalona, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005

Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumorsAlejandro D Ricart, Lisa A Hammond, John G Kuhn, et al.

Seminars in Oncology|October 3, 2003

Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupChris H Takimoto, Scot C Remick, Sunil Sharma, et al.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 4, 2003

Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancerChris H Takimoto, Kira Glover, Xiaoke Huang, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003

A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignanciesAmita Patnaik, S Gail Eckhardt, Elzbieta Izbicka, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal functionAlain C Mita, Christopher J Sweeney, Sharyn D Baker, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007

Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal functionChris H Takimoto, Martin A Graham, Graham Lockwood, et al.

Pageof 3

Search research articles

Showing results (11-20 of 21) with videos related to

Sort By:

Pageof 3

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignanciesEric K Rowinsky, Jinee Rizzo, Leonel Ochoa, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005

Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomasJames A Posey, M Wasif Saif, Ronda Carlisle, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005

Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumorsAlejandro D Ricart, Lisa A Hammond, John G Kuhn, et al.

Seminars in Oncology|October 3, 2003

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 4, 2003

Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancerChris H Takimoto, Kira Glover, Xiaoke Huang, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007

Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal functionChris H Takimoto, Martin A Graham, Graham Lockwood, et al.

Pageof 3